VEOS PHARMACEUTICALS, SL (Absorbing Company) and VEOS VENTURES, SL (Absorbed Company)
Announcement of merger agreement by absorption.
In compliance with the provisions of Article 10 of Royal Decree-Law 5/2023, it is hereby made public that, on March 11, 2026, the respective partners of the participating companies unanimously approved the merger by absorption of Veos Ventures, SL as the absorbed company by Veos Pharmaceuticals, SL as the absorbing company.
The operation is carried out with extinction, via dissolution without liquidation of the absorbed company, and transfer in block of all its assets to the absorbing company, without any capital increase in this company, which will acquire by universal succession all the rights, obligations and legal relationships of the absorbed company.
The merger balance sheets closed as of December 31, 2025 were also approved. The merger agreement was adopted in accordance with the joint merger plan signed on March 4, 2026 by the respective joint administrators of the companies participating in the merger.
Simplified regime
The approved merger is carried out in accordance with the simplified regime provided for in articles 53 and 56 of Royal Decree-Law 5/2023 , as it is a merger of companies wholly owned directly or indirectly by the same partners and with identical participation in the participating companies.
Furthermore, the merger falls under Article 9 of Royal Decree-Law 5/2023. For this reason, it has been approved without the need to publish or deposit the documents required in Royal Decree-Law 5/2023 beforehand, and without an announcement regarding the possibility of submitting comments or a report from the administrators on the draft amendment, as per the terms of the aforementioned Article 9.
Rights of partners and creditors
In accordance with Article 10 of Royal Decree-Law 5/2023, the right of the partners and creditors of the companies participating in the merger to obtain the full text of the agreements adopted and the merger balance sheets, which are available to them at the corresponding registered office, is hereby stated.
In accordance with the provisions of Article 13 of Royal Decree-Law 5/2023, the participating companies do not consider it necessary to offer guarantees to creditors, who may exercise the rights recognized therein.
Mr. Bassam Bahij Damaj,
in his capacity as joint administrator of Veos Pharmaceuticals, SL and Veos Ventures, SL
Media & Investor Contact
Veos Pharmaceuticals, S.L.
Calle Núñez de Balboa, 35 A-5 Planta Oficina A1
28001 Madrid, Spain
Email: info@veospharma.com
Telephone: +34 911 925 649
Website: www.veospharma.com